Kidney cancer: The role of metastasectomy in metastatic renal cell carcinoma

Nature Reviews Urology

Volumn 8, Issue 4, 2011, Pages 180-181

  Staehler, Michael ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT;

ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LUNG METASTASIS; METASTASIS RESECTION; METASTATIC RENAL CELL CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; KIDNEY TUMOR; LUNG TUMOR; METASTASIS; MORTALITY; NOTE; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; NEOPLASM METASTASIS; SURVIVAL RATE;

EID: 79953878386     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.30     Document Type: Article

References (9)

1. Alt, A. L. et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer doi:10.1002/cncr.25836.
2. Motzer, R. J. et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 22, 454-463 (2004). (Pubitemid 41079774)
3. Heng, D. Y et al. Prognostic factors for overal survival in patients with metastatic renal cel carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27, 5794-5799 (2009).
4. Winter, H. et al. Tumor infiltrated hilar and mediastinal lymph nodes are an independent prognostic factor for decreased survival after pulmonary metastasectomy in patients with renal cell carcinoma. J. Urol. 184, 1888-1894 (2010).
5. Fottner, A. et al. Bone metastases from renal cell carcinoma: patient survival after surgical treatment. BMC Musculoskelet Disord. 11, 145 (2010).
6. Karam, J. A. et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J. Urol. 185, 439-444 (2011).
7. Staehler, M. D. et al. Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J. Urol. 28, 543-547 (2010).
8. Ebos, J. M., Lee, C R., Christensen, J. G., Mutsaers, A. J. & Kerbel, R. S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc. Natl Acad. Sci. USA 104, 17069-17074 (2007). (Pubitemid 350210993)
9. Johannsen, M. et al. Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy Ann. Oncol. 22, 657-663 (2010).